Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Celt Health is a clinical-stage biotechnology company focused on developing oral small molecule therapies for inflammatory and autoimmune diseases. The company's lead candidate, CELT-101, is an oral inhibitor of IL-17A and IL-17F, designed to provide a more convenient alternative to injectable biologics for conditions like psoriasis and hidradenitis suppurativa. By targeting the IL-17 pathway with a small molecule, Celt Health aims to improve patient access and compliance while maintaining high efficacy. The company is headquartered in San Diego and is led by a team with extensive experience in immunology and drug development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Celt Health.